【作者】 苏珊珊；

【导师】 张法荣；

【作者基本信息】 山东中医药大学 ， 中医内科学， 2008， 硕士

【摘要】 目的:研究和评价古方黑地黄丸治疗慢性肾功能衰竭脾肾两虚兼湿浊证的临床疗效及安全性,为其临床应用提供客观依据。方法:采用前瞻性、随机、阳性药物平行对照方法,共纳入225例病人,其中试验组111例和对照组114例,由3家临床试验单位共同完成。分别服用黑地黄丸和肾康宁。两组均连续口服用药2个月,结束疗程。分别观察和检测两组治疗前后临床症状、肾功能及血RBC、HGB的情况。结果:1.试验组黑地黄丸慢性肾功能衰竭总有效率为80.56%,显著优于对照组肾康宁63.39%,p<0.01;2.试验组黑地黄丸可降低血Scr水平,升高Ccr水平,与对照组相比有显著性差异,p<0.01;p<0.05。3.试验组黑地黄丸治疗后可显著提高患者血RBC、血HGB水平,P<0.01;对照组治疗前后血RBC、HGB比较,p>0.05,无统计学意义;两组间比较无显著性差异。结论:黑地黄丸可改善患者临床症状,保护肾功能,改善贫血,可延缓慢性肾衰病程进展。更多还原

【Abstract】 Objective: To study and evaluate the clinical efficacy and safety of the ancient prescription HeidiHuang wan in treating chronic renal failure with both spleen and kidney deficiency and dampness. Methods: Take the method of prospective, randomized, parallel positive drug control to observe 225 cases of the CRF patients ,the test group of 111 cases and 114 cases of the control group. the test group were treated HeidiHuang wan and the control group were treated ShenkangNing. observe clinical symptoms and Detection the level of renal function and Red blood cell and Hemoglobin of the two groups after two months treatment by oral medication. Results: 1.The total efficiency of test group is 80.56%,which is significantly better than the control group(63.39%), p<0.01. 2. Test group HeidiHuang wan can reduce the blood Creatinine level(p <0.05) and increased Ccr level (p<0.01), there was significant difference compared with the control group, p <0.01, p <0.05.3. HeidiHuang wan can significantly increase The level of Red blood cell and Hemoglobin, P <0.01. Red blood cell and Hemoglobin after treatment of control group compared with The level before treatment has no statistical significance, p> 0.05. Conclusion: HeidiHuang can improve clinical symptoms, protect the renal function and improve anemia. It can delay the progression of chronic renal failure.更多还原